GPAM and steatosis: The first is that AAA-1 promote hepatocyte steatosis in vitro and in vivo, most likely by increasing lipogenesis due to the selective upregulation of SREBP-1 and the transient activation of two key enzymes involved in triglyceride synthesis (FASN and GPAT-1).